Charlie Gourley
University of Edinburgh · Edinburgh Cancer Research Centre, The University of Edinburgh
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Charlie Gourley as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:58 UTC. Open this list on ClinicalTrials.gov
- N/ANCT04532645 · Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UKAstraZeneca · completed · Ovary Cancer · principal investigator
- Ph2NCT03268382 · p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246Aprea Therapeutics · completed · High-grade Serous Ovarian Cancer · principal investigator
- Ph3NCT02392676 · Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes MutationsAstraZeneca · withdrawn · Platinum Sensitive Relapsed Ovarian Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:58 UTC. The ranking covers the 200 most relevant of 36 PubMed records, and a shared surname and initials can bring in a namesake. All 36 on PubMed
- 2,326 citationsRCR 81.5
- A phase 3 trial of bevacizumab in ovarian cancer.N Engl J Med · 20111,749 citationsRCR 45.0
- Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.N Engl J Med · 20121,491 citationsRCR 36.1
- 1,161 citationsRCR 32.0
- Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.J Clin Oncol · 2010805 citationsRCR 16.9
- Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.J Clin Oncol · 2023441 citationsRCR 39.9
- 378 citationsRCR 9.4
- 358 citationsRCR 10.2
- 329 citationsRCR 17.3
- 205 citationsRCR 13.3